A Phase 1b First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

Brief description of study

The purpose of the study is to determine the safety and tolerability of the antibody-drug conjugate (ADC) XMT-1536 administered as an intravenous infusion once every four weeks. We want to know how the drug works and the maximum tolerated dose. The investigational drug in this study is XMT-1536 Antibody Drug Conjugate (ADC), which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval,for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s20-00317
ClinicalTrials.gov Identifier: NCT03319628
Principal Investigator: Bhavana Pothuri.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.